- Labcorp (LH, Financial) expands its precision oncology portfolio with two new diagnostic solutions.
- Innovative tests target stage III colon cancer recurrence and provide faster treatment selection for solid tumors.
- Labcorp Plasma Detect and PGDx elio plasma focus Dx set to improve patient outcomes and cancer diagnostics.
Labcorp (LH), a global leader in laboratory services, has significantly advanced its precision oncology offerings by launching two novel solutions aimed at enhancing cancer diagnostics and treatment options.
The first solution, Labcorp Plasma Detect, is a blood-based test that employs whole-genome sequencing to assess the risk of recurrence in stage III colon cancer patients, who face a nearly 30% recurrence rate within five years. By detecting circulating tumor DNA (ctDNA) at a limit of 0.005%, the test provides early warnings of cancer recurrence, offering results approximately 14 days after receiving samples.
The second offering, PGDx elio plasma focus Dx, is the first FDA-authorized kitted pan-solid tumor liquid biopsy test. It allows for patient treatment selection through a straightforward blood draw, delivering results in just 4-5 days. This test enables clinical laboratories to maintain control over specimens and requires only on-site verification for implementation.
Both solutions highlight Labcorp's dedication to advancing cancer diagnostics, with presentations planned for the AACR 2025 Annual Meeting in Chicago.
